Frontiers in Psychology (Aug 2023)
Effects of ozone therapy on anxiety and depression in patients with refractory symptoms of severe diseases: a pilot study
- Bernardino Clavo,
- Bernardino Clavo,
- Bernardino Clavo,
- Bernardino Clavo,
- Bernardino Clavo,
- Bernardino Clavo,
- Bernardino Clavo,
- Bernardino Clavo,
- Angeles Cánovas-Molina,
- Angeles Cánovas-Molina,
- Angeles Cánovas-Molina,
- Juan A. Díaz-Garrido,
- Silvia Cañas,
- Yolanda Ramallo-Fariña,
- Yolanda Ramallo-Fariña,
- Yolanda Ramallo-Fariña,
- Yolanda Ramallo-Fariña,
- Horus Laffite,
- Mario Federico,
- Delvys Rodríguez-Abreu,
- Saray Galván,
- Carla García-Lourve,
- Carla García-Lourve,
- Damián González-Beltrán,
- Miguel A. Caramés,
- Jose L. Hernández-Fleta,
- Pedro Serrano-Aguilar,
- Pedro Serrano-Aguilar,
- Francisco Rodríguez-Esparragón,
- Francisco Rodríguez-Esparragón,
- Francisco Rodríguez-Esparragón,
- Francisco Rodríguez-Esparragón
Affiliations
- Bernardino Clavo
- Research Unit, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain
- Bernardino Clavo
- Chronic Pain Unit, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain
- Bernardino Clavo
- Radiation Oncology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain
- Bernardino Clavo
- Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC), Las Palmas de Gran Canaria/Tenerife, Spain
- Bernardino Clavo
- Universitary Institute for Research in Biomedicine and Health (iUIBS), Molecular and Translational Pharmacology Group, University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain
- Bernardino Clavo
- Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias de la Universidad de La Laguna, Santa Cruz de Tenerife, Spain
- Bernardino Clavo
- CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
- Bernardino Clavo
- Spanish Group of Clinical Research in Radiation Oncology (GICOR), Madrid, Spain
- Angeles Cánovas-Molina
- Research Unit, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain
- Angeles Cánovas-Molina
- Chronic Pain Unit, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain
- Angeles Cánovas-Molina
- Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC), Las Palmas de Gran Canaria/Tenerife, Spain
- Juan A. Díaz-Garrido
- Psychiatry Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain
- Silvia Cañas
- 0Psychiatry Department, Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Las Palmas de Gran Canaria, Spain
- Yolanda Ramallo-Fariña
- Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC), Las Palmas de Gran Canaria/Tenerife, Spain
- Yolanda Ramallo-Fariña
- 1Network for Research on Chronicity, Primary Care, and Health Promotion (RICAPPS), Santa Cruz de Tenerife, Spain
- Yolanda Ramallo-Fariña
- 2Servicio de Evaluación y Planificación del Servicio Canario de Salud (SESCS), Santa Cruz de Tenerife, Spain
- Yolanda Ramallo-Fariña
- 3Instituto de Tecnologías Biomédicas (ITB), Universidad de la Laguna, Santa Cruz de Tenerife, Spain
- Horus Laffite
- Psychiatry Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain
- Mario Federico
- Radiation Oncology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain
- Delvys Rodríguez-Abreu
- 4Medical Oncology Department, Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Las Palmas de Gran Canaria, Spain
- Saray Galván
- 5Medical Oncology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain
- Carla García-Lourve
- Research Unit, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain
- Carla García-Lourve
- Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC), Las Palmas de Gran Canaria/Tenerife, Spain
- Damián González-Beltrán
- Research Unit, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain
- Miguel A. Caramés
- Chronic Pain Unit, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain
- Jose L. Hernández-Fleta
- Psychiatry Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain
- Pedro Serrano-Aguilar
- Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC), Las Palmas de Gran Canaria/Tenerife, Spain
- Pedro Serrano-Aguilar
- 3Instituto de Tecnologías Biomédicas (ITB), Universidad de la Laguna, Santa Cruz de Tenerife, Spain
- Francisco Rodríguez-Esparragón
- Research Unit, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain
- Francisco Rodríguez-Esparragón
- Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC), Las Palmas de Gran Canaria/Tenerife, Spain
- Francisco Rodríguez-Esparragón
- Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias de la Universidad de La Laguna, Santa Cruz de Tenerife, Spain
- Francisco Rodríguez-Esparragón
- CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
- DOI
- https://doi.org/10.3389/fpsyg.2023.1176204
- Journal volume & issue
-
Vol. 14
Abstract
BackgroundPatients with refractory symptoms of severe diseases frequently experience anxiety, depression, and an altered health-related quality of life (HRQOL). Some publications have described the beneficial effect of ozone therapy on several symptoms of this kind of patient. The aim of this study was to preliminarily evaluate, in patients treated because of refractory symptoms of cancer treatment and advanced nononcologic diseases, if ozone therapy has an additional impact on self-reported anxiety and depression.MethodsBefore and after ozone treatment, we assessed (i) anxiety and depression according to the Hospital Anxiety and Depression Scale (HADS); (ii) the HRQOL (according to the EQ-5D-5L questionnaire), which includes a dimension on anxiety and depression and a visual analog scale (VAS) measuring self-perceived general health.ResultsBefore ozone therapy, 56% of patients were on anxiolytic and/or antidepressant treatment. Before and after ozone therapy, the anxiety and depression HADS subscales (i) significantly correlated with the anxiety/depression dimension of the EQ-5D-5L questionnaire and (ii) inversely correlated with the health status as measured by the VAS. After ozone therapy, we found a significant improvement in anxiety and depression measured by both the (i) HADS subscales and (ii) EQ-5D-5L questionnaire.ConclusionThe addition of ozone therapy for patients with refractory symptoms of cancer treatment and advanced chronic nononcologic diseases can decrease anxiety and depression severity levels. Additional, more focused studies are ongoing to provide the needed explanatory information for this finding.
Keywords
- ozone therapy
- anxiety and depression
- health-related quality of life
- advanced diseases
- chemotherapy-induced side effects
- radiation-induced side effects